1. Search Result
Search Result
Results for "

Retinoic acid receptors

" in MedChemExpress (MCE) Product Catalog:

108

Inhibitors & Agonists

4

Fluorescent Dyes

5

Biochemical Assay Reagents

5

Natural
Products

13

Isotope-Labeled Compounds

4

GMP Molecules

Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-14649
    Retinoic acid
    Maximum Cited Publications
    127 Publications Verification

    Vitamin A acid; all-trans-Retinoic acid; ATRA

    Organoid RAR/RXR PPAR Endogenous Metabolite Autophagy Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha.
    Retinoic acid
  • HY-107202
    Polyinosinic-polycytidylic acid
    60+ Cited Publications

    Poly(I:C)

    RIG-I-like receptor (RLR) Toll-like Receptor (TLR) PKD HSP Bcl-2 Family Interleukin Related Apoptosis Infection Inflammation/Immunology Cancer
    Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis .
    Polyinosinic-polycytidylic acid
  • HY-135748

    Poly(I:C) sodium

    RIG-I-like receptor (RLR) Toll-like Receptor (TLR) Apoptosis Inflammation/Immunology Cancer
    Polyinosinic-polycytidylic acid (Poly(I:C)) sodium is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid sodium can directly trigger cancer cells to undergo apoptosis .
    Polyinosinic-polycytidylic acid sodium
  • HY-14652
    Tamibarotene
    5+ Cited Publications

    Am 80

    RAR/RXR Autophagy Apoptosis Cancer
    Tamibarotene is an orally active retinoic acid receptor α (RARα) agonist, showing high selectivity over RARγ.
    Tamibarotene
  • HY-15373
    Fenretinide
    5+ Cited Publications

    4-HPR; ISLA-101

    RAR/RXR Autophagy Cancer
    Fenretinide (4-HPR) is a synthetic retinoid deriverative, binding to the retinoic acid receptors (RAR) at concentrations necessary to induce cell death.
    Fenretinide
  • HY-108529
    BMS493
    5+ Cited Publications

    RAR/RXR Metabolic Disease
    BMS493 is an inverse pan-retinoic acid receptor (RAR) agonist. BMS493 increases nuclear corepressor interaction with RARs. BMS493 also could prevent retinoic acid-induced differentiation . BMS493 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    BMS493
  • HY-U00449
    AGN 193109
    5+ Cited Publications

    RAR/RXR Cancer
    AGN 193109 is a retinoid analog, and acts as a specific and highly effective antagonist of retinoic acid receptors (RARs), with Kds of 2 nM, 2 nM, and 3 nM for RARα, RARβ, and RARγ, respectively. AGN 193109 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. AGN 193109 is the antidote for retinoic acidosis, that ameliorates the skin and mucosal toxicity.
    AGN 193109
  • HY-14422
    SR1078
    10+ Cited Publications

    ROR Cancer
    SR1078 is a selective agonist of retinoic acid receptor-related orphan receptor α/γ (RORα/RORγ). SR1078 directly binds to the ligand binding domain of RORα and RORγ and increases the transcriptional activity of these receptors, leading to stimulation of RORα/γ target gene transcription .
    SR1078
  • HY-14649R
    Retinoic acid (Standard)
    Maximum Cited Publications
    127 Publications Verification

    Vitamin A acid (Standard); all-trans-Retinoic acid (Standard); ATRA (Standard)

    Reference Standards RAR/RXR PPAR Endogenous Metabolite Autophagy Cancer
    Retinoic acid (Standard) is the analytical standard of Retinoic acid. This product is intended for research and analytical applications. Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha.
    Retinoic acid (Standard)
  • HY-116248
    Ro 41-5253
    3 Publications Verification

    RAR/RXR Apoptosis Cancer
    Ro 41-5253 is an orally active selective retinoic acid receptor alpha (RARα) antagonist. Ro 41-5253 can bind RARα without inducing transcription or affecting RAR/RXR heterodimerization and DNA binding. Ro 41-5253 can inhibit cancer cell proliferation and induce apoptosis, has antitumor activity .
    Ro 41-5253
  • HY-101106
    AR7
    10+ Cited Publications

    RAR/RXR Neurological Disease Cancer
    AR7 is an atypical RARA/RARα (retinoic acid receptor, alpha) antagonist. AR7 specifically activates chaperone-mediated-autophagy (CMA) activity without affecting macroautophagy .
    AR7
  • HY-100532
    CD437
    4 Publications Verification

    AHPN

    RAR/RXR Autophagy Cancer
    CD437 is a selective Retinoic Acid Receptor γ (RARγ) agonist.
    CD437
  • HY-14649G

    Vitamin A acid; all-trans-Retinoic acid; ATRA

    RAR/RXR PPAR Endogenous Metabolite Autophagy Cancer
    Retinoic acid (Vitamin A acid) (GMP) is Retinoic acid (HY-14649) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Retinoic acid is an agonist of RAR nuclear receptors .
    Retinoic acid
  • HY-14799
    Palovarotene
    10+ Cited Publications

    R 667; Ro 3300074

    RAR/RXR Autophagy Others
    Palovarotene is a nuclear retinoic acid receptor γ (RAR-γ) agonist.
    Palovarotene
  • HY-15388
    Tazarotene
    2 Publications Verification

    AGN 190168

    RAR/RXR Autophagy Inflammation/Immunology Cancer
    Tazarotene (AGN 190168) is a selective retinoic acid receptor (RAR) agonist for the treatment of plaque psoriasis and acne vulgaris. Tazarotene is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Tazarotene
  • HY-107765
    LY2955303
    4 Publications Verification

    RAR/RXR Autophagy Inflammation/Immunology
    LY2955303 is a potent and selective retinoic acid receptor gamma (RARγ) antagonist with a Ki of 1.09 nM.
    LY2955303
  • HY-107397
    Ch55
    2 Publications Verification

    RAR/RXR Cancer
    Ch55 is a potent synthetic retinoid. Ch55 binds to RAR-α and RAR-β receptors with high affinity. Ch55 displays low affinity for cellular retinoic acid binding protein (CRABP). Ch55 is a potent inducer of the differentiation of HL60 cells with an EC50 of 200 nM. Ch55 can be used for cancer research .
    Ch55
  • HY-108522
    PA452
    1 Publications Verification

    RAR/RXR Metabolic Disease
    PA452, retinoic X receptor (RXR) specific antagonist, inhibits the effect of Retinoic acid (RA) on Th1/Th2 development .
    PA452
  • HY-100008
    Peretinoin
    5+ Cited Publications

    NIK333

    RAR/RXR SphK Autophagy HCV Infection Cancer
    Peretinoin is an oral acyclic retinoid with a vitamin A-like structure that targets retinoid nuclear receptors such as retinoid X receptor (RXR) and retinoic acid receptor (RAR). Peretinoin reduces the mRNA level of sphingosine kinase 1 (SPHK1) in vitro by downregulating a transcription factor, Sp1 . Peretinoin prevents the progression of non-alcoholic steatohepatitis (NASH) and the development of hepatocellular carcinoma (HCC) through activating the autophagy pathway by increased Atg16L1 expression . Peretinoin inhibits HCV RNA amplification and virus release by altering lipid metabolism with a EC50 of 9 μM .
    Peretinoin
  • HY-107395

    RAR/RXR Inflammation/Immunology
    BMS 753 is an isotype-selective retinoic acid receptor α (RARα) agonist, with a Ki of 2 nM .
    BMS 753
  • HY-101108
    Tazarotenic acid
    2 Publications Verification

    AGN 190299

    Drug Metabolite Others
    Tazarotenic acid is the metabolite of Tazarotene. Tazarotenic acid binding to retinoic acid receptors (RARs) is the probable molecular target of retinoid action. Tazarotenic acid has the potential for the research of warty dyskeratoma .
    Tazarotenic acid
  • HY-125904
    4-Hydroxyretinoic acid
    1 Publications Verification

    RAR/RXR UGT Cytochrome P450 Apoptosis Drug Derivative Neurological Disease Inflammation/Immunology Cancer
    4-Hydroxyretinoic acid (4-HRA) is a derivative of Retinoic acid (HY-14649). 4-Hydroxyretinoic acid is formed via the catalysis of retinol by cytochrome P-450 isoenzymes. 4-Hydroxyretinoic acid also serves as a substrate for UDP-glucuronosyltransferase (s) and recombinant UGT2B7. 4-Hydroxyretinoic acid binds to the nuclear receptor RAR (Retinoic Acid Receptor), activates RAR and RXR-alpha, subsequently regulates gene expression and cell differentiation, and induces cancer cell apoptosis (Apoptosis). 4-Hydroxyretinoic acid also participates in multiple physiological processes such as immunoregulation, neuroprotection and antioxidation .
    4-Hydroxyretinoic acid
  • HY-107494A
    all-trans-4-Oxoretinoic acid
    1 Publications Verification

    all-trans 4-Keto Retinoic acid

    Endogenous Metabolite Metabolic Disease
    all-trans-4-Oxoretinoic acid, an active metabolite of vitamin A, induces gene transcription via binding to nuclear retinoic acid receptors (RARs).
    all-trans-4-Oxoretinoic acid
  • HY-14649S4

    Vitamin A acid-d5; all-trans-Retinoic acid-d5; ATRA-d5

    Isotope-Labeled Compounds RAR/RXR PPAR Endogenous Metabolite Autophagy Cancer
    Retinoic acid-d5 is the the deuterium labeled Retinoic acid (HY-14649). Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha .
    Retinoic acid-d5
  • HY-108528

    RAR/RXR Inflammation/Immunology
    BMS961 is a selective retinoic acid receptor-γ (RARγ) agonist. BMS961 shows anti-inflammatory activity .
    BMS961
  • HY-108532

    RAR/RXR Cancer
    AC-261066 is a potent, orally available and isoform-selective retinoic acid beta2 (RARbeta2) receptor agonist, with a pEC50 of 8.0 .
    AC-261066
  • HY-134958

    Poly(I:C) potassium

    Toll-like Receptor (TLR) Apoptosis Inflammation/Immunology Cancer
    Polyinosinic-polycytidylic acid potassium (Poly(I:C) potassium) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid potassium can directly trigger cancer cells to undergoApoptosis .
    Polyinosinic-polycytidylic acid potassium
  • HY-15682G

    Ro 13-7410; Arotinoid acid; AGN191183

    RAR/RXR Cancer
    TTNPB (Ro 13-7410) (GMP) is TTNPB (HY-15682) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TTNPB is a highly potent retinoic acid receptor (RAR) agonist .
    TTNPB
  • HY-119518

    BMS-209641

    RAR/RXR Cancer
    BMS641 (BMS-209641) is a selective RARβ agonist. BMS641 has a higher affinity for RARβ (Kd, 2.5 nM) that is 100 times higher than that for RARα (Kd, 225 nM) or RARγ (Kd, 223 nM) .
    BMS641
  • HY-112706

    ROR Inflammation/Immunology
    PF-06747711 is a potent, selective, and orally active retinoic acid receptor-related orphan C2 (RORC2, also known as RORγt) inverse agonist, with an IC50 of 4.1 nM. Anti-skin inflammatory activity .
    PF-06747711
  • HY-14653

    TAC-101; Am 555S

    RAR/RXR Apoptosis Cancer
    Amsilarotene (TAC-101; Am 555S), an orally active synthetic retinoid, has selective affinity for retinoic acid receptor α (RAR-α) binding with Ki of 2.4, 400 nM for RAR-α and RAR-β. Amsilarotene induces the apoptotic of human gastric cancer, hepatocellular carcinoma and ovarian carcinoma cells. Amsilarotene can be used for the research of cancer .
    Amsilarotene
  • HY-156280

    RAR/RXR Endocrinology
    RARα antagonist 1 (compound 21) is an orally active and selective retinoic acid receptor α(RARα) antagonist, with the IC50 of 4.6nM .
    RARα antagonist 1
  • HY-117545

    RAR/RXR Cancer
    LE-540 is a selective retinoic acid receptor antagonist for RARβ (Ki=0.22 μM). LE-540 shows potential for use in cancer research, particularly for breast cancer and lung cancer .
    LE-540
  • HY-105689

    RAR/RXR Others
    AGN 192870 is a RAR neutral antagonist with Kds of 147, 33, and 42 nM for RARα, RARβ, and RARγ, respectively. AGN 192870 shows IC50s of 87 and 32 nM for RARαand RARγ, respectively. AGN 192870 shows RARβ partial agonism . AGN 192870 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    AGN 192870
  • HY-153165

    RAR/RXR Others
    RXR antagonist 5 (compound 22) is a selective retinoic acid X receptor (RXR) antagonist with binding potential to RXR evaluated by modeling.
    RXR antagonist 5
  • HY-W150866

    Hexylparaben

    ROR Inflammation/Immunology
    Hexyl 4-hydroxybenzoate (Hexylparaben) is a retinoic acid-related orphan receptor RORγ(t) agonist with an EC50 of 144 nM. Hexyl 4-hydroxybenzoate is used in the study of autoimmune diseases .
    Hexyl 4-hydroxybenzoate
  • HY-119464
    MRL-871
    1 Publications Verification

    ROR Cancer
    MRL-871 (compound 3) is a potent and allosteric retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonists with an IC50 of 12.7 nM. MRL-871 has a distinct isoxazole chemotype and effectively reduces IL-17a mRNA production in EL4 cells .
    MRL-871
  • HY-113827

    Nuclear Hormone Receptor 4A/NR4A Inflammation/Immunology
    THPN is a potent Nur77 agonist. THPN specifically binds the LBD of Nur77 (TR3) but not that of retinoic acid receptor α and PPARγ with a Kd of 270 nM. THPN leads to Nur77 translocation to the mitochondria to induce autophagic cell death in melanoma .
    THPN
  • HY-111509

    ROR Inflammation/Immunology
    TAK-828F is a potent, selective, and orally available retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist (binding IC50=1.9 nM, reporter gene IC50=6.1 nM). TAK-828F shows excellent RORγt isoforms selectivity (>5000-fold selectivity against human RORα and RORβ) .
    TAK-828F
  • HY-119366

    ROR Inflammation/Immunology
    S18-000003 is a potent, selective and orally active inhibitor of retinoic acid receptor-related orphan receptor-gamma-t (RORγt), with an IC50 of <30 nM towards human RORγt in competitive binding assays. S18-000003 shows selectivity for RORγt over other ROR family members (IC50>10 μM). S18-000003 can be used for the research of psoriasis with low risk of thymic aberrations .
    S18-000003
  • HY-108520

    RAR/RXR Apoptosis Cancer
    HX630 is a potent retinoic acid X receptor (RXR) agonist, can induce apoptosis, has anti-tumor effect, and can be used in Cushing's disease research .
    HX630
  • HY-114071

    RAR/RXR Cancer
    BMS270394 is a nuclear retinoic acid receptor (RAR-γ) agonist with the EC50 values of 30 nM and 400 nM for humanRAR-γ and RAR-β, respectively .
    BMS270394
  • HY-106735

    Ro 13-6298; Arotinoid ethyl ester

    RAR/RXR Inflammation/Immunology Cancer
    Arotinoid (RO 13-6298) is a retinoid, and acts as an orally active and highly potent agonist of retinoic acid receptors (RARs) with antipsoriatic effects. Arotinoid has antipapiltoma activity with an ED50 of 0.05 mg/kg. Arotinoid can be used for the research of skin carcinomas .
    Arotinoid
  • HY-120785

    ROR Inflammation/Immunology
    SR1555 is a specific retinoic acid receptor-related orphan nuclear receptor γ (RORγ) inverse agonist with an IC50 value of 1 μM. SR1555 not only inhibits TH17 cell development and function but also increases the frequency of T regulatory cells, as well as inhibits the expression of IL-17. SR1555 can be used for researching autoimmune diseases .
    SR1555
  • HY-124136
    WYC-209
    1 Publications Verification

    RAR/RXR Apoptosis Autophagy Cancer
    WYC-209, a synthetic retinoid, is a retinoic acid receptor (RAR) agonist. WYC-209 induces apoptosis primarily via the caspase 3 pathway (IC50=0.19 μM for inmalignant murine melanoma TRCs), and has long-term effects with little toxicity .
    WYC-209
  • HY-W587468

    3,4-DHRA

    Biochemical Assay Reagents
    All-trans-3,4-Didehydro retinoic acid (3,4-DHRA) is a compound with gene-regulating activity that binds to retinoic acid receptors (RARs) and triggers receptor activation. All-trans-3,4-Didehydro retinoic acid plays an important role in skin development and differentiation and has potential anti-tumor and anti-inflammatory properties. All-trans-3,4-Didehydro retinoic acid is also being studied for the inhibition of a variety of diseases, including skin diseases and certain types of cancer.
    all-trans-3,4-Didehydro retinoic acid
  • HY-108531A

    RAR/RXR Cancer
    ER 50891 quarterhydrate is a RARα antagonist. ER 50891 can significantly antagonize the inhibitory effect of all-trans retinoic acid (ATRA) on the total cell metabolic activity and proliferation of MC3T3-E1 preosteoblasts. ER 50891 rescues ATRA-inhibited osteocalcin (OCN) expression and extracellular matrix mineralization, and suppresses alkaline phosphatase (ALP) activity synergistically. ER 50891 can be used for the study of osteoporosis related to ATRA-induced inhibition of osteoblastogenesis .
    ER 50891 quarterhydrate
  • HY-16983

    ROR Inflammation/Immunology
    GNE-3500 is a selective, orally active antagonist for Retinoic Acid Receptor-Related Orphan Receptor C (RORc, also known as RORγ or NR1F3) with an EC50 of 12 nM. GNE-3500 exhibits good pharmacokinetic characteristics in rats .
    GNE-3500
  • HY-133128

    ROR Cancer
    FM26 (compound 25) is a potent and allosteric retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonists with an IC50 of 264 nM. FM26 has a distinct isoxazole chemotype and effectively reduces IL-17a mRNA production in EL4 cells .
    FM26
  • HY-107810

    RAR/RXR Cancer
    Methyl 13-cis-4-oxoretinoate (Compound 4b) is a retinoic acid receptors (RARs) agonist. Methyl 13-cis-4-oxoretinoate is promising for research of dermatological diseases (e.g., disorders related to abnormal differentiation of keratinocytes) and cancers .
    Methyl 13-cis-4-oxoretinoate

온라인 문의

Your information is safe with us. * Required Fields.

호칭

 

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

 

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: